南非宫颈癌组织中的人乳头瘤病毒类型：通过mRNA和DNA检测进行的直接比较
HPV types in cervical cancer tissue in South Africa: A head-to-head comparison by mRNA and DNA tests.
作者信息
Rad Amir, Sørbye Sveinung Wergeland, Dreyer Greta, Hovland Siri, Falang Bente Marie, Louw Melanie, Skjeldestad Finn Egil
机构信息
Department of Community Medicine, Faculty of Health Sciences, UiT The Arctic University of Norway Department of Clinical Pathology, University Hospital of North Norway, Tromsø, Norway Department of Obstetrics and Gynaecology, University of Pretoria, Pretoria, South Africa PreTect AS, Klokkarstua, Norway Department of Anatomical Pathology, University of Pretoria, Pretoria, South Africa.
出版信息
Medicine (Baltimore). 2017 Nov;96(47):e8752. doi: 10.1097/MD.0000000000008752.
Accurate identification of human papillomavirus (HPV)-types in cervical cancer tissue may be important for tailoring tests for primary screening and types to be included in a vaccine. The aim of this study was to compare test-performance of a 45-type HPV deoxyribonucleic acid (DNA)-test with a 9-type HPV messenger ribonucleic acid (mRNA)-test in cervical cancer tissues.In a case-series design 188 women with diagnosed cervical cancer during the period January 2008 to July 1, 2011 at the Gynaecological Oncology Unit, University of Pretoria, South Africa were recruited to the study. After cases with negative internal controls for DNA/mRNA detection (n = 18) and unconfirmed histology (n = 3) of cervical cancer were excluded, 167 women remained eligible for analysis. We compared 45 DNA-types detected through general primer (GP)5/6 polymerase chain reaction (PCR) and reverse line blot (RLB) genotyping with a modified version of the mRNA test PreTect HPV-Proofer detecting 9 genotypes (16, 18, 31, 33, 35, 45, 51, 52, 58).Histological types were 92.2% squamous cell carcinoma, 4.8% adenocarcinoma, and 3.0% adenosquamous carcinoma. Overall, HPV was detected in 95.2% (159/167) of specimens. The DNA- and mRNA tests each rendered 153/167 (91.6%) HPV positive results. When restricting the analysis to the 9 high-risk HPV-types included in the mRNA test, 91.6% (153/167) and 88.0% (147/167) were positive by the mRNA- and DNA-tests (P = .28), respectively. After hierarchical categorization of 9 comparable types, we found concordance in 66 of 67 specimens for HPV16, 25 of 27 specimens for HPV18, 19 of 21 specimens for HPV45, and only in 33 of 45 for HPV31, 33, 35, 51, 52, 58. The positivity rate for the HPV types 16, 18, and 45 and the positivity rate for HPV 16, 18, 45, 33 and 35 by both tests was 66% to 68% and 80% to 83%, respectively.Overall and when considering established high-risk types, the mRNA test has at least as high detection rate as the DNA test. The mRNA test can be an appropriate research tool to describe causative HPV-types in cervical cancer tissue for health care planning purposes.
准确鉴定宫颈癌组织中的人乳头瘤病毒（HPV）类型，对于定制初级筛查检测方法以及确定疫苗所涵盖的HPV类型可能具有重要意义。本研究的目的是比较45型HPV脱氧核糖核酸（DNA）检测法与9型HPV信使核糖核酸（mRNA）检测法在宫颈癌组织中的检测性能。
在一项病例系列设计研究中，招募了2008年1月至2011年7月1日期间在南非比勒陀利亚大学妇科肿瘤病房确诊为宫颈癌的188名女性。排除DNA/mRNA检测内部对照阴性的病例（n = 18）以及宫颈癌组织学诊断未确诊的病例（n = 3）后，167名女性仍符合分析条件。我们将通过通用引物（GP）5/6聚合酶链反应（PCR）和反向线印迹（RLB）基因分型检测到的45种DNA类型，与检测9种基因型（16、18、31、33、35、45、51、52、58）的改良版mRNA检测法PreTect HPV-Proofer进行了比较。
组织学类型为92.2%的鳞状细胞癌、4.8%的腺癌和3.0%的腺鳞癌。总体而言，95.2%（159/167）的标本检测到HPV。DNA检测和mRNA检测均得出153/167（91.6%）的HPV阳性结果。当将分析限制在mRNA检测所包含的9种高危HPV类型时，mRNA检测和DNA检测的阳性率分别为91.6%（153/167）和88.0%（147/167）（P = 0.28）。在对9种可比类型进行分层分类后，我们发现HPV16的67个标本中有66个一致，HPV18的27个标本中有25个一致，HPV45的21个标本中有19个一致，而HPV31、33、35、51、52、58的45个标本中只有33个一致。两种检测方法中HPV16、18和45型的阳性率以及HPV16、18、45、33和35型的阳性率分别为66%至68%和80%至83%。
总体而言，以及在考虑既定的高危类型时，mRNA检测法的检测率至少与DNA检测法一样高。mRNA检测法可以作为一种合适的研究工具，用于描述宫颈癌组织中致病的HPV类型，以进行医疗保健规划。
Zotero 插件